[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
[3] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[4] |
Anna C Zhao-Wong, ZHU Lilin.
An introduction to the Medical Dictionary for Regulatory Activities and its use
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 74-78.
|
[5] |
TIAN Chunhua, LIU Wei, LIU Cuili, HOU Yongfang, WANG Dan.
Progress in Implementation of ICH M1 in Post-marketing Monitoring of Drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 763-765.
|
[6] |
HOU Yongfang, TIAN Chunhua, LIU Hongliang, LIU Cuili, LI Ming, WANG Xinmin.
Study on Applicability of ICH Guideline M1 Mapping Practice of National Adverse Drug Reaction Terminology
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 333-337.
|
[7] |
MA Danhua, LIU Hongliang, WANG Dan, LI Ming, TIAN Chunhua.
Study on Applicability of ICH Guideline M1 Mapping Feasibility of National Adverse Drug Reaction Terminology
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 329-332.
|
[8] |
XU Xiaodi.
Review of the Studies on the Knowledge, Attitude and Practice toward Adverse Drug Reactions Reporting among Different Reporting Entity at Home and Abroad
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 239-243.
|
[9] |
ZHONG Lumiao.
MAHs’ Principal Responsibilities for Safety Risk during the Whole-life Cycle of Drugs
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 666-669.
|
[10] |
YANG Yue.
Problems and Solutions to Implementation of Direct Reporting of Adverse Reaction System by MAHs
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 649-653.
|
[11] |
BAO Hui-ling, LI Jiang-fan, WU Zhi-ang.
Analysis on Influencing Factors of Quality of Adverse Drug Reaction Reports in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 226-229.
|
[12] |
ZHU Lan, REN Jingtian, GUAN Wei, LIU Hongliang.
Analysis of Crucial Elements in Published Case Reports of Drug-induced Liver Injury
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 663-667.
|
[13] |
LI Qing-na,LU Fang,ZHAO Yang,GAO Hong-yang,GAO Rui.
A Preliminary Study on Establishing the Set of Terms for Coding Clinical Trials of TCM Based on MedDRA Terminology
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(1): 53-55.
|
[14] |
SUN Jun, WEI Zhen, LI Ming.
Investigation of Pharmaceutical Manufacturers' Establishments on Management System for Monitoring and Reporting Adverse Drug Reactions
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(1): 8-11.
|
[15] |
DONG Duo, SUN Li-hua.
Study of Guideline for Drug Man ufacturer on Adverse Drug Reaction Reporting and Monitoring with Delphi Method
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(9): 523-526.
|